Her-Vaxx Update clearly explained ala "The Professor"

Thx for that post. I agree 100% with your expectations of a sponsored trial with an approved drug. I posted this yesterday. LC has stated clearly on several occasions that partnering with a big selling approved drug was the way forward.

She had recently flagged how excited she was about our next trials/steps with HerVAX.

It is likely that the sponsored trial announcement is the big one that shareholders have been waiting for. That’s why the whales have been scooping up as many shares as they can.

As always the small retailers selling out of fear. LC has been exceptionally good at communicating with the market. If holders don’t have the knowledge to understand the announcement or piece together the details , they should practice restraint and not make decisions based on fear or greed.

It was always going to happen, that the whales will own a bigger and bigger percentage of IMU as the small retailers drop off the perch. If they are not highly experienced at trading they shoukd just sit tight.

As Alex Wailitsz from Thorney Investment said “ buy and hold a technology share that’s going to change the world, like IMUGENE “.

As a chemo nurse, I have noticed there are a couple of obvious benefits that HER-vaxx has over Herceptin. It seems they are overlooked or not widely recognised in this forum. No doubt these will big factors when it comes to approval and commercialisation of HER-Vaxx.

1. From my understanding, HER-vaxx is a subcutaneous injection whilst Herceptin is a 30 minute IV infusion. Obviously it would be much easier, safer and cheaper to just get a quick injection under the skin.

2. Herceptin can cause damage to the heart. Baseline and regular checks of the heart LVEF (left ventricular ejection fraction) is required for patients having Herceptin. I am not sure if this is the case for HER Vaxx. Herceptin otherwise has very minimal reported side effects. Given it has been claimed that HER-vaxx has a better side effect profile than Herceptin, one can take an educated guess that heart function may not be affected and may not require monitoring with HER Vaxx. Therefore less costly heart scans. Less appointments for patients and takes some pressure off the hospital system.

With these two factors considered, approval and commercialing of HER-vaxx should be favourable, even if its efficacy was not a lot greater than herceptin.

Of course this is my own opinion and not advice. DYOR.